Drug Abuse Testing Market Report by Product & Service, Sample Type, Drug Type, End Users, Countries and Company Analysis 2026-2034

Drug Abuse Testing Market Size and Forecast

Drug Abuse Testing Market is projected to grow from US$ 6.64 Billion in 2025 to US$ 12.03 Billion by 2034, expanding at a CAGR of 6.83% during 2026–2034. The market is anticipated to witness steady growth due to rising concerns surrounding substance abuse, increasing adoption of workplace drug screening programs, and stringent regulatory requirements across safety-sensitive industries. Growing demand for rapid, accurate, and convenient testing solutions is further supporting market expansion.

What is Drug Abuse Testing and Its Uses & Popularity Worldwide

Drug abuse testing refers to the screening and analytical process used to detect the presence of illicit drugs, prescription-drug misuse, or their metabolites in biological samples such as urine, blood, saliva, hair, and sweat. Testing can identify substances including cannabis, cocaine, opioids, amphetamines, methamphetamine, and other controlled drugs. It is widely used in workplaces, hospitals, rehabilitation centers, forensic laboratories, sports organizations, law enforcement agencies, and transportation industries. Testing methods range from rapid immunoassay kits and point-of-care tests to laboratory-based chromatographic and mass-spectrometry techniques.

Worldwide demand is supported by the continuing prevalence of drug use and the need to improve safety, treatment, and monitoring. UNODC estimates that approximately 331 million people used drugs worldwide in 2024, representing a 34% increase from 2014. Cannabis remained the most widely used drug, with an estimated 256 million users. Increasing substance-use awareness, workplace safety requirements, clinical monitoring, and regulatory screening programs are therefore contributing to the broad adoption of drug abuse testing technologies.

Global Trends in Cocaine-Related Mortality: 2010–2023 Indexed Comparison

·United States (Synthetic Opioid Co-Involvement Surge):

• Cocaine + Synthetic Opioids (Other than Methadone): Exhibits the sharpest rise on the chart, rocketing from near-zero levels (<10) prior to 2014 to an index value exceeding 160 by 2023, reflecting widespread contamination/co-use with illicit fentanyl.
• Cocaine Without Synthetic Opioids: Climbed earlier (peaking around index 120 in 2017), briefly dipped toward 2020, and climbed again to reach ~130 by 2023.

·France:

• Shows a steep post-2014 acceleration, spiking rapidly from 2020 (100) to nearly 160 by 2022, marking one of the highest recent growth rates in Europe.

·United Kingdom & Canada:

• United Kingdom: Maintained very low relative levels in the early 2010s (~10–15), rising steadily to reach approximately 130 by 2023.
• Canada: Rose sharply through 2018–2021 and continued upward to around 130 by 2023.

·Brazil:

• Started at an index level of ~60 in 2010, stabilized between 60–80 for most of the decade, and climbed to peak at ~120 around 2022 before a slight drop in 2023.

·Italy:

• Remained relatively flat between 2017 and 2022 (~80–100), but experienced a visible downturn by 2023 to drop below 80.

·Australia:

• Followed an upward trajectory through 2019–2020 (reaching the 100 baseline), but saw a consistent post-2020 decline, falling to roughly 70 by 2022.

Growth Drivers of the Drug Abuse Testing Market

Rising Global Drug Use and Substance Abuse Concerns

The increasing prevalence of drug use worldwide is creating greater demand for reliable testing and monitoring solutions. According to the UNODC World Drug Report 2026, an estimated 331 million people used drugs in 2024, representing a 34% increase compared with 2014, while the prevalence of drug use increased by approximately 20%. Cannabis accounted for about 256 million users, followed by non-medical opioid use at 63 million. This expanding population of drug users increases the need for screening in healthcare, rehabilitation, forensic, workplace, and public-safety settings. Drug testing can support early identification of substance exposure, treatment monitoring, compliance assessment, and investigations. In the United States, SAMHSA reported that 73.6 million people aged 12 or older, or 25.5%, used an illicit drug during 2024, compared with 62.0 million in 2021. Such trends encourage healthcare providers, employers, and public agencies to adopt faster and more accessible testing technologies. Consequently, growing substance-use concerns are expanding the potential testing population and supporting market demand.

Increasing Workplace Drug Screening and Safety Requirements

Workplace drug screening is an important application area for drug abuse testing because organizations in transportation, construction, manufacturing, healthcare, energy, and other safety-sensitive industries seek to identify substance use that could increase occupational risks. Employers may use pre-employment, random, post-incident, reasonable-suspicion, or return-to-duty testing depending on applicable regulations and workplace policies. The expansion of safety programs and regulatory compliance requirements encourages demand for urine, oral-fluid, hair, and rapid screening technologies. Testing programs can also support organizations in maintaining documented compliance and reducing risks associated with substance impairment. In the United States, federal workplace drug-testing programs operate under established technical and regulatory requirements, while other countries maintain their own occupational-testing frameworks. The continuing global burden of substance use reinforces the relevance of workplace screening. UNODC estimated that 331 million people used drugs in 2024, demonstrating the scale of potential exposure across populations and workplaces. As employers increasingly prioritize occupational safety, compliance, and faster screening, demand for convenient and accurate testing solutions is expected to increase.

Technological Advancements in Rapid and Point-of-Care Testing

Technological innovation is transforming drug abuse testing by improving testing speed, portability, sensitivity, and ease of use. Conventional laboratory analysis remains important for confirmatory testing, but rapid immunoassay kits and point-of-care platforms can provide preliminary results closer to the location of testing. Oral-fluid testing is also gaining attention because samples can be collected more conveniently and can help detect relatively recent drug exposure. Modern laboratory technologies, including chromatography and mass spectrometry, provide highly specific confirmation and can identify multiple substances within a single analytical workflow. These innovations are particularly valuable for workplaces, emergency departments, rehabilitation programs, law enforcement, and roadside or field-based screening. The increasing diversity of substances also encourages laboratories to expand testing panels and analytical capabilities. UNODC has highlighted the rapid expansion of synthetic drugs and reported record seizures of amphetamine-type stimulants in 2023, emphasizing the changing nature of the drug landscape. As testing providers respond with multiplex assays, automated workflows, digital reporting, and portable devices, technological advancement is expected to remain a significant contributor to market expansion.

Challenges of the Drug Abuse Testing Market

Accuracy, False Results, and Need for Confirmatory Testing

Maintaining high analytical accuracy is a major challenge because drug-testing results can be affected by sample quality, cross-reactivity, detection windows, medications, testing procedures, and the characteristics of individual assays. Rapid screening tests are generally designed to provide preliminary results and may require laboratory confirmation when a positive result has significant medical, employment, legal, or regulatory consequences. Confirmatory methods such as mass spectrometry can improve specificity but require specialized equipment, trained personnel, quality-control procedures, and additional time and cost. The growing variety of synthetic drugs and novel psychoactive substances further complicates detection because conventional panels may not cover newly emerging compounds. UNODC has reported rapid expansion of the synthetic drug market, illustrating how quickly the substance landscape can change. Testing laboratories must therefore continually update analytical methods and substance panels. These requirements can increase operating costs and create challenges for organizations seeking inexpensive, rapid testing. Maintaining validated methodologies, appropriate cutoffs, quality assurance, and confirmatory procedures remains essential for reliable drug abuse testing.

Privacy, Regulatory, and Ethical Concerns

Drug abuse testing involves sensitive personal information, making privacy, data protection, informed consent, and appropriate interpretation important challenges for market participants. Workplace and healthcare testing programs must comply with applicable laws governing employee rights, medical information, sample handling, reporting, and laboratory standards. Requirements can differ substantially between countries and even across industries, increasing compliance complexity for testing providers operating internationally. Ethical concerns may also arise when test results influence employment, treatment, insurance, legal proceedings, or other important decisions. Appropriate chain-of-custody procedures and secure handling of test results are particularly important when results may have legal or occupational consequences. At the same time, WHO emphasizes the importance of strengthening prevention and treatment responses for substance-use disorders worldwide. This creates a need to use testing as part of appropriate healthcare and public-health strategies rather than relying on screening results alone. Regulatory compliance, privacy safeguards, staff training, and secure data management can increase implementation costs and complexity, potentially limiting adoption among smaller organizations and facilities.

Drug Abuse Treatment Launches Worldwide

1. Brixadi – United States, 2023
   Braeburn’s Brixadi (buprenorphine) extended-release injection was approved by the U.S. FDA for the treatment of moderate-to-severe opioid use disorder. It introduced weekly and monthly subcutaneous dosing options, expanding medication-assisted treatment choices for patients with opioid dependence.
2. Zurnai – United States, 2024
   FDA approved Zurnai, an auto-injector containing nalmefene hydrochloride, in August 2024 for emergency treatment of known or suspected opioid overdose in adults and pediatric patients aged 12 years and older. It became the first nalmefene hydrochloride auto-injector approved in the United States.
3. Amneal OTC Naloxone Nasal Spray – United States, 2024
   Amneal launched an over-the-counter 4 mg naloxone hydrochloride nasal spray in April 2024 following FDA approval. The generic product was introduced to expand access to emergency treatment for opioid overdose without requiring a prescription.
4. Walgreens Naloxone Nasal Spray – United States, 2024
   Walgreens introduced its own over-the-counter naloxone nasal spray in 2024 after receiving FDA approval. The product was made available through Walgreens stores and its online platform, adding another retail distribution channel for opioid-overdose reversal treatment.
5. RESET® and RESET-O® – United States, 2024
   PursueCare introduced RESET and RESET-O, FDA-authorized prescription digital therapeutics for substance use disorder and opioid use disorder. The app-based programs provide a structured 12-week cognitive behavioral therapy course designed to complement clinical addiction treatment.
6. Pelago Cannabis Use Disorder Treatment Program – United States, 2024
   Pelago introduced a dedicated digital treatment program for cannabis use disorder in April 2024. The program expanded its existing digital substance-use services, which included treatment support for tobacco, alcohol, and opioids, with implementation planned for the third quarter of 2024.
7. Awakn Kare Treatment Expansion – United States, 2024
   Awakn Life Sciences launched an additional licensing partnership in Oklahoma in April 2024 to expand access to its Awakn Kare treatment protocol for alcohol use disorder. The partnership provided local practitioners with access to the company’s treatment protocol, therapeutics, and associated training.
8. British Columbia Opioid Treatment Access Line – Canada, 2024
   British Columbia launched a provincewide Opioid Treatment Access Line in August 2024. The service was designed to provide faster access to medications for opioid use disorder and connect individuals with same-day treatment and care, reducing barriers to entering treatment.
9. Charlie Health Substance Use Disorder Program – United States, 2025
   Charlie Health launched a dedicated virtual treatment program in April 2025 for people whose primary condition is substance use disorder. The program covers conditions involving alcohol, opioids, and other substances and builds on the company’s experience treating co-occurring mental-health and substance-use conditions.
10. Sublocade New Dosing Regimen – United States, 2025
    FDA approved a new dosing regimen for Sublocade (buprenorphine extended-release injection) in 2025 for opioid use disorder. The revised regimen allows patients to receive Sublocade after only one sublingual buprenorphine dose rather than the previous seven-day requirement, representing a change intended to simplify treatment initiation.

Growing Demand for Automated and Multi-Drug Detection

The analyzers segment comprises automated instruments used to identify drugs and their metabolites in biological specimens, including urine, blood, and oral fluid. Major technologies include immunoassay analyzers, chromatography systems, and mass-spectrometry platforms. Demand is increasing as laboratories and healthcare facilities seek higher throughput, standardized workflows, and reliable results. Analyzers are particularly important for confirmatory and high-volume testing, where automation can reduce manual handling and improve laboratory efficiency. The drugs-of-abuse testing market is also increasingly segmented into immunoassay analyzers, chromatography-based analyzers, and mass-spectrometry systems. Digital reporting, laboratory information-system integration, multiplex testing, and improved portability are further supporting adoption. Growing drug-use prevalence is another fundamental demand factor, with UNODC estimating that 331 million people used drugs worldwide in 2024, increasing the need for screening and analytical capacity.

Convenience and Rapid Collection Support Saliva-Based Testing

The oral fluid drug abuse testing segment uses saliva samples to detect drugs or their metabolites and is increasingly used where rapid, convenient sample collection is required. Oral fluid testing can reduce some of the logistical challenges associated with urine collection because specimens can generally be collected under direct observation without the same degree of privacy required for urine sampling. Applications include workplace screening, roadside and law-enforcement testing, clinical settings, and other point-of-care environments. The U.S. Substance Abuse and Mental Health Services Administration (SAMHSA) provides dedicated federal resources covering both urine and oral-fluid workplace drug testing, reflecting the established role of saliva-based testing within workplace programs. Technological advances are improving portability, testing speed, and multi-drug detection capabilities. However, oral fluid generally has a shorter detection window than some other specimen types, meaning the method is particularly suited to applications focused on relatively recent exposure. Its ease of collection and growing regulatory acceptance continue to support worldwide demand.

Rising Cannabis Use and Regulatory Screening Requirements

The cannabis or marijuana drug abuse testing segment is expanding as cannabis consumption increases and employers, healthcare providers, law-enforcement agencies, and other organizations require methods to identify cannabis exposure. Testing can use urine, oral fluid, blood, hair, and emerging breath-based technologies, depending on the intended application and detection window. UNODC reported that approximately 256 million people used cannabis in 2024, making cannabis the most widely used drug worldwide. The organization also reported that cannabis use increased by 34% over the 2014–2024 period. This substantial user population supports continued demand for THC and metabolite testing. Workplace programs are another important application, with SAMHSA identifying drug testing as a prevention and deterrence component of comprehensive drug-free workplace programs. Oral-fluid tests are gaining relevance where organizations seek convenient collection and relatively recent-use detection, while laboratory mass spectrometry remains important for confirmatory analysis. A major technical challenge is that the presence of THC or its metabolites does not necessarily establish the exact time of use or current impairment. Consequently, testing providers are developing more sophisticated approaches, including improved oral-fluid assays and technologies intended to complement conventional biological testing.

Expansion of Specialized Toxicology and Confirmation Services

The drug testing laboratories segment includes specialized facilities that perform screening, confirmation, and quantitative analysis of drugs and their metabolites for healthcare, workplace, forensic, criminal-justice, and other applications. Laboratory testing remains important when an initial screening result requires greater analytical specificity. Common technologies include immunoassays for screening and chromatography coupled with mass spectrometry for confirmatory analysis. Market demand is supported by the growing global burden of drug use: UNODC estimated that 331 million people used drugs in 2024, up 34% from 2014. Laboratories therefore face increasing requirements to detect established substances as well as emerging synthetic drugs and novel psychoactive substances. The World Drug Report 2026 notes that the number of new psychoactive substances identified by Member States since 2005 had approached 1,500 by 2025, illustrating the continually changing analytical landscape. Workplace testing is another established source of laboratory demand, with SAMHSA maintaining certified laboratory lists and electronic custody-and-control requirements for federal programs. Laboratories are increasingly investing in automation, high-throughput analyzers, digital reporting, expanded testing panels, and advanced mass-spectrometry capabilities. Outsourcing of specialized testing by hospitals, employers, and smaller laboratories can further expand demand, while partnerships and laboratory consolidation may help providers broaden geographic coverage and analytical capabilities.

United States Regulatory Screening and High Substance-Use Prevalence Support Demand

United States drug abuse testing market is supported by substantial substance-use activity, established workplace screening programs, healthcare applications, and regulatory requirements across safety-sensitive industries. According to the 2025 National Survey on Drug Use and Health (NSDUH), approximately 69.8 million Americans aged 12 or older, or 24.0% of the population, reported illicit drug use in 2025. Marijuana accounted for 61.6 million users, while 6.9 million people reported prescription opioid misuse and 4.2 million reported cocaine use. This large testing population supports demand for urine, oral-fluid, blood, hair, and laboratory-based testing technologies. Workplace testing remains an important application, particularly in transportation and other safety-sensitive sectors subject to federal requirements. Healthcare providers and rehabilitation facilities also use drug testing for screening, treatment monitoring, and clinical assessment. In addition, law-enforcement agencies increasingly require portable testing technologies for roadside and field applications. Demand is further supported by investments in opioid and stimulant monitoring, automated laboratory analyzers, rapid immunoassays, and confirmatory chromatography-mass spectrometry systems.

Germany Cannabis Consumption and Toxicology Screening Expand Testing Requirements

Germany’s drug abuse testing market is being supported by increasing cannabis consumption, established healthcare infrastructure, workplace screening, and forensic toxicology requirements. According to Germany’s Federal Ministry of Health, a 2024 survey estimated that 5.05 million adults aged 18–64 had consumed cannabis at least once during the previous 12 months, representing 12.3% of men and 7.1% of women. Government data also indicate that cannabis use among adults increased from 4.5% in 2012 to 9.7% in 2024, while 6.1% of people aged 12–17 reported use during the previous year. These trends support demand for screening and confirmatory testing across healthcare, occupational, forensic, and law-enforcement settings. Oral-fluid screening can provide convenient sample collection for roadside and workplace applications, while laboratory-based chromatography and mass spectrometry remain important for confirmation and quantitative analysis. Germany’s regulatory environment also creates demand for accurate documentation and reliable analytical procedures. Growing attention to cannabis-related safety, alongside monitoring of cocaine and other stimulants, is encouraging laboratories to expand testing panels and analytical capabilities.

India Substance-Using Population Creates Opportunities for Screening Technologies

India’s drug abuse testing market is expanding alongside growing awareness of substance-use disorders, healthcare screening requirements, workplace safety initiatives, and the development of diagnostic infrastructure. India’s National Survey on Extent and Pattern of Substance Use, conducted through NDDTC-AIIMS, estimated that about 3.1 crore people used cannabis products and 2.26 crore people used opioids. The government also estimates that approximately 77 lakh people require help for opioid-use problems and around 25 lakh require help for cannabis-use problems. Government data from the survey reported current cannabis use at approximately 2.8% of the surveyed 10–75 population and opioid use at approximately 2.1%. These figures create demand for drug screening across hospitals, de-addiction centers, diagnostic laboratories, forensic facilities, and selected workplace environments. Rapid urine and oral-fluid test kits are particularly useful where preliminary screening is required quickly, while advanced laboratories use confirmatory analytical techniques. Adoption is also being supported by greater awareness among employers and healthcare providers. However, cost, uneven laboratory infrastructure, and limited awareness in some rural areas remain factors influencing market penetration.

Saudi Arabia Strong Regulatory Controls and Healthcare Investment Support Market Development

Saudi Arabia’s drug abuse testing market is supported by strict controls on illicit substances, workplace and occupational screening requirements, healthcare modernization, and investment in laboratory infrastructure. Drug testing is relevant across healthcare facilities, forensic laboratories, transportation and other safety-sensitive workplaces, and law-enforcement applications. The country’s healthcare transformation under Vision 2030 is encouraging modernization of diagnostic infrastructure and wider adoption of digital and laboratory technologies. Demand is also influenced by the need for reliable toxicology screening and confirmation as authorities address substance misuse and trafficking. Testing providers can serve this environment through rapid urine and oral-fluid screening kits, automated immunoassay analyzers, and laboratory confirmation using chromatography and mass spectrometry. Increasing digitalization of healthcare can further support electronic reporting, laboratory information-system integration, and centralized monitoring of test results. Saudi Arabia’s broader substance-use response includes prevention, treatment, and rehabilitation activities, creating demand beyond law-enforcement testing. As healthcare facilities and specialized laboratories expand their analytical capabilities, the market can benefit from greater availability of rapid and high-throughput testing technologies, while stringent regulatory requirements continue to emphasize accuracy, documentation, and controlled sample handling.

Drug Abuse Market Testing Market Segments

Product & Service

• Analysers
• Rapid Testing Devices
• Consumables
• Laboratory Services

Sample Type

• Urine
• Oral Fluid
• Breath
• Hair
• Others

Drug Type

• Alcohol
• Cannabis/Marijauna
• Cocaine
• Opioids
• Amphetamine & Methaphetamine
• LSD
• Others

End User

• Drug Testing Laboratories
• Workplaces
• Hospitals
• Rehabilitation Centers
• Academic Institutes and Research Centers
• Others

Countries

North America

• United States
• Canada

Europe

• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Turkey

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Thailand
• Malaysia
• Indonesia
• New Zealand

Latin America

• Brazil
• Mexico
• Argentina

Middle East & Africa

• South Africa
• Saudi Arabia
• United Arab Emirates

All companies have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

• Danaher Corporation
• LabCorp
• Abbott Laboratories
• Quest Diagnostics
• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche Ltd.
• Bio-Rad Laboratories Ltd.
• Medtronic Plc.

Report Details: